| Antibody composition |
2022-5-12 |
2022-11-17 |
|
| Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
2022-1-07 |
2022-7-14 |
|
| Anti-interleukin 36 receptor (il-36r) therapy for acne |
2022-1-07 |
2022-7-14 |
|
| Pd-1 agonist and method of using same |
2021-11-24 |
2022-1-01 |
|
| Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
2021-10-27 |
2022-6-02 |
|
| B and t lymphocyte attenuator (btla) modulators and method of using same |
2021-10-22 |
2022-4-28 |
|
| dostarlima |
2021-9-28 |
2021-9-28 |
|
| Antibodies Directed Against Programmed Death-1 (PD-1) |
2021-9-27 |
2022-3-24 |
|
| Antibodies directed against programmed death-1 (pd-1) |
2021-8-26 |
2021-9-28 |
|
| Antibodies directed against interleukin 36 receptor (il-36r) |
2021-8-26 |
2021-12-16 |
|
| Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis |
2021-7-30 |
2022-2-03 |
|
| Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
2021-7-30 |
2022-2-03 |
|
| Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
2021-5-06 |
2021-6-30 |
|
| Antibodies Directed Against Lymphocyte Activation Gene 3 (LAG-3) |
2020-10-19 |
2021-4-01 |
|
| Antibodies directed against interleukin-33 (il-33) |
2020-10-15 |
2021-2-11 |
|
| Anti-il-33 antibody for use in treating eosinophilic asthma |
2019-9-23 |
2020-3-26 |
|
| Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor |
2019-3-25 |
2019-9-26 |
|
| Anti-IL-33 therapy for atopic dermatitis |
2018-10-09 |
2019-6-16 |
|
| Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses … |
2018-4-27 |
2022-5-05 |
|
| Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
2017-11-01 |
2018-7-16 |
|
| Antibodies directed against programmed death- 1 (pd-1) |
2017-11-01 |
2018-7-16 |
|
| Inhibition of allergic reaction using an il-33 inhibitor |
2017-1-17 |
2019-1-17 |
|
| Pd-1 binding proteins and methods of use thereof |
2016-9-28 |
2017-3-30 |
|
| Antibodies against interleukin 36 receptor (IL-36R) |
2016-4-15 |
2023-4-07 |
|
| Antibodies directed against Lymphocyte Activation Gene 3 (LAG-3) |
2016-2-03 |
2017-9-14 |
|
| Antibodies directed against Lymphocyte Activation Gene 3 (LAG-3) |
2016-2-03 |
2021-4-29 |
2021-4-29 |
| Antibodies directed against discoidin domain receptor family, member 1 (ddr1) |
2015-1-27 |
2015-8-06 |
|
| Antibodies directed against nerve growth factor (ngf) |
2014-12-31 |
2015-4-30 |
|
| Antibodies directed against programmed death-1 (PD-1) |
2014-5-02 |
2022-3-01 |
|
| Antibodies directed against programmed death-1 (pd-1) |
2014-5-02 |
2022-1-06 |
|
| Antibodies directed against activin receptor type ii (actrii) |
2014-4-16 |
2015-1-08 |
|
| Methods of generating libraries and uses thereof |
2014-2-14 |
2016-2-16 |
2016-2-16 |
| Thermostable antibody framework regions |
2013-9-19 |
2014-3-20 |
|
| Humanized antibodies directed against complement protein C5 |
2013-8-21 |
2015-9-15 |
2015-9-15 |
| Use of somatic hypermutation to create insertion and deletion mutations in … |
2012-10-19 |
2013-4-25 |
|
| Antibodies directed against IL-17 |
2011-8-02 |
2013-3-21 |
|
| Method of producing transcripts using cryptic splice sites |
2011-3-15 |
2013-2-07 |
|
| Methods of generating improved antigen-binding agents using chain shuffling and … |
2010-11-03 |
2012-9-12 |
|
| Isolation of antibodies that cross-react and neutralize rankl orginating from … |
2007-9-28 |
2008-7-24 |
|
| Isolation of antibodies that cross-react and neutralize rankl originating from … |
2007-9-28 |
2008-5-08 |
|
| In vivo affinity maturation scheme |
2003-12-18 |
2004-7-09 |
|
| In vivo affinity maturation scheme |
2003-12-18 |
2006-1-11 |
|
| 针对白细胞介素36受体（il-36r）的抗体 |
2016-4-15 |
2023-4-07 |
|